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Abstract
Background: In type 1 multiple endocrine neoplasia (MEN1), esophageal diseases association with excessive gastrin
secretion in Zollinger-Ellison syndrome (ZES) sometimes develop. Here, we reported a case of MEN1/ZES, who
developed dysphagia due to reflux esophagitis with severe esophageal stricture. Treatment for his esophageal
stricture and ZES was discussed.
Case presentation: A 43-year-old man with progressive dysphagia and diarrhea was referred to the teaching
hospital. He had a history of recurrent duodenojejunal perforations despite the anti-secretory medication. Blood
examinations revealed elevated serum gastrin, calcium, and parathyroid hormone. Upper gastrointestinal endoscopy
demonstrated a severe esophageal stricture, multiple gastroduodenal ulcer scars, and a duodenal submucosal
tumor. Enhanced computed tomography showed multiple hypervascular tumors within the pancreas and
duodenum, suggestive of MEN1. Genetic examination demonstrated a pathogenic MEN1 mutation. Repetitive
endoscopic esophageal dilatation with intralesional corticosteroid injection, coupled with pancreatoduodenectomy
were performed to improve the patient’s symptoms and to treat pancreatic tumors. The histology of multiple
tumors in the duodenum and pancreas were all consistent with neuroendocrine tumors. His hypergastrinemia
subsided and he remained asymptomatic in his gastrointestinal tract after these treatments.
Conclusion: For esophageal stenosis in case of MEN1/ZES, anti-secretory therapy and endoscopic dilatation with
corticosteroid injection could be recommended. However, in refractory cases with repetitive and/or severe
complications due to high acid secretion, surgical treatment could be considered as an option.
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Background
Type 1 multiple endocrine neoplasia (MEN1) is an auto-
nomic dominant hereditary syndrome that carries a life-
time risk of developing an endocrine neoplasm in ≥95%
of cases. Clinical diagnostic criteria require two or more
of the following three items: 1) hyperparathyroidism; 2)
pancreatic endocrine neoplasm; and 3) pituitary neo-
plasm. Germline mutation of the MEN1 gene is recog-
nized in 80–90% of familial cases and in about 65% of
sporadic cases [1]. They are sometimes associated with
gastrinomas [Zollinger-Ellison syndrome (ZES)] [1],
which induce gastric hypersecretion and cause not only
gastroduodenal ulcers but also reflux esophagitis [2], in
combination with hypercalcemia due to hyperparathyr-
oidism. Heartburn is a typical symptom of reflux esopha-
gitis and is recognized in about 50% of cases of MEN1.
Anti-acid therapies, such as proton pump inhibitors
(PPI) and H2 receptor antagonists, are effective [2].
MEN1 with ZES also develops dysphagia due to esopha-
geal strictures in a small proportion (9%) [2], and their
endoscopic treatment has rarely been reported. This re-
port presents a case of MEN1 with ZES that developed
esophageal strictures which were successfully treated
with repetitive procedures of endoscopic dilation with
local steroid injection combined with duodenectomy
and total pancreatectomy.
Case presentation
A 43-year-old man visited the nearest hospital for exam-
ination of his increasing complaints of nausea and diar-
rhea for 4 years and recent development of dysphagia.
He had a history of duodenal ulcer perforation, and
underwent omental patching surgery 4 years earlier,
followed by oral treatment with a PPI (30 mg/day of lan-
soprazole). Octreotide analog was not used. Upper
gastrointestinal endoscopy (UGE) demonstrated reflux
erosive esophagitis with severe esophageal stricture.
Plain computed tomography (CT) showed a urinary tract
stone and a pancreatic mass. Despite continuous anti-
acid therapy, perforation of the small intestine
developed, and he underwent closure surgery. Using the
selective arterial secretagogue injection (SASI) test, a re-
sponse by calcium injection was obtained when exam-
ined from the superior mesenteric artery, which
connects to the feeding arteries to either the pancreatic
head, body, or tail. However, it was not obtained by the
examinations from the gastroduodenal artery and splenic
artery.
The patient was referred to the study hospital to fur-
ther investigate the suspected diagnosis of MEN1. Blood
examination revealed an elevated level of serum gastrin
(≥3000 pg/mL, normal: ≤200 pg/mL), glucagon (253 pg/
mL, normal: 70–174 pg/mL), calcium (10.9 mg/dL, nor-
mal: 8.5–10.2 mg/dL) and intact-parathyroid hormone
(PTH) (104 pg/mL, normal: 10–65 pg/mL). Enhanced
CT demonstrated multiple highly vascular lesions within
the pancreas (head to tail) and duodenum, with up to
20 mm in the pancreas (Fig. 1). UGE demonstrated
healing of the esophageal erosion, however the sten-
osis at the lower esophagus, approximately 4 mm in
diameter and 5 cm in length, became so severe that
only a slim endoscope (Olympus GIF-XP260, Tokyo,
Japan), but not a standard scope (Olympus GIF-
H260), could pass through. Multiple gastroduodenal
ulcer scars were observed. In the second portion of
the duodenum, a submucosal tumor, 12 mm in size,
was also recognized (Fig. 2).
Considering these findings associated with hypergastri-
nemia, it was planned to treat the esophageal stricture
and neuroendocrine tumors prior to the treatment of
the hyperparathyroidism. Balloon dilator treatment
(CRETM, 15–18 mm, Boston Scientific, Marlborough,
MA, U.S.A.) (Fig. 2) was repeated 16 times, before and
after the total pancreatectomy with duodenectomy, until
the disappearance of the esophageal stricture. The inter-
val between each procedure was almost once a week for
the first 10 procedures, except for the month of the sur-
gical period, followed by two weeks for the 11th-12th
procedures, and one to three months for the 13th-16th
procedures. Balloon dilation was done for 30–60 s with
Fig. 1 Enhanced computed tomography showing multiple highly vascular tumors within the pancreas and the duodenum; a well demarcated
duodenal tumor protruding into the lumen (a), a tumor at the head (b), body (c), and tail (d) of the pancreas
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pressure stepped up as in the following: limited up to
1.5–2 atm for the initial five procedures, 3–4 atm for the
next five procedures, and 4–5 atm for the remaining
procedures. Since full dilation was not obtained until the
5th procedure, 50 mg (5 ml) of triamcinolone acetonide
(Kenacort-A, Bristol-Myers Squibb, New York, U.S.A.)
was injected to the stenotic portion at the 6th-8th pro-
cedure. In detail, 0.5–1.0 ml of triamcinolone acetonide
solution was injected into 5–8 sites within the stenosis
using an injection needle (NeedleMaster, 26 Gy,
Olympus, Tokyo, Japan) each after the balloon dilation.
The patient’s symptoms and stricture had disappeared
by the 15th procedure, and the 16th dilation was per-
formed at the patient’s request (Fig. 2).
Total pancreatectomy with duodenectomy was per-
formed for the multiple masses within the pancreas as
well as in the duodenum. Extent of the pancreatectomy
was arguable as the result of SASI test was not well in-
formative, to remove possible functional PNET and pos-
sible future malignant lesions, total pancreatectomy was
performed. This operation was done between the 2nd
and 3rd esophageal dilation procedures. The histology of
the multiple tumors in the pancreas (4) and duodenum
(1) was entirely neuroendocrine tumor (NET), with
histological grade 2 (G2). PNETs were recognized in all
parts of pancreas (head, body and tail). Immunostaining
of gastrin was strongly positive within the duodenal
tumor, but only faintly recognized in the pancreatic tu-
mors (Fig. 3). The clinical diagnosis of MEN1 was con-
firmed with these histological results.
Genetic counseling [3] was completed and his family
history was pursued. It was revealed that his father and
one of two sisters had hyperparathyroidism, and his
father also had a NET with further details unavailable.
The patient hoped to have a genetic examination per-
formed after giving informed consent. Germline patho-
genic mutation of the MEN1 gene was detected by
whole exon analysis using next generation sequencer
(Ion ProtonTM system, Thermo Fisher Scientific,
Waltham, MA, U.S.A.), which was employed in the on-
going institutional project [4], and was confirmed by the
commercial base analysis (Falco biosystems, Kyoto,
Fig. 2 Endoscopic view of the esophageal stenotic portion (a), dilation with a balloon catheter (b), corticosteroid injection by a needle (c), at the
last observation (d), and the duodenal submucosal tumor (e)
Fig. 3 Gastrin expression in the neuroendocrine tumors of the duodenum (a) and pancreas (b) (Gastrin, x100); nested or diffuse expression in the
duodenal tumor (a) in contrast to faint expression in the pancreatic tumor (b)
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Japan). This information was expected to be used for
him and his family in their future medical treatment. To
date, his hypergastrinemia improved and he remained
asymptomatic after the treatments for 28 months. With
taking pancrelipase and insulin injection, his nutrition
level and blood glucose level kept in good condition.
Discussion
This case of MEN1 with pancreaticoduodenal gastrino-
mas, accompanied with a high level of serum gastrin
(≥3000 pg/mL, normal: ≤200 pg/mL), developed severe
esophageal stenosis and complained of dysphagia, des-
pite administration of full-dose PPI. He also had re-
peated histories of duodenojejunal perforations. To treat
this condition, repetitive esophageal endoscopic dilations
were performed for local therapy and resection of the
pancreaticoduodenal NETs for removing the causative
lesion of acid hypersecretion.
Benign esophageal stricture can occur in various disor-
ders in adults. For mild to moderate levels of strictures,
peptic injury and Schatzki’s ring or web [5] can be
causative diseases. Severe strictures can result from
caustic ingestion, radiation injury, anastomotic stricture,
photodynamic therapy, and/or endoscopic submucosal
dissection-related ulcer scar [6–8]. For benign esopha-
geal strictures, endoscopic dilation is usually applied in a
stepwise manner depending on its severity [6, 9]. Dila-
tion using a wire-guided polyvinyl dilator (e.g. Savary-
Gilliard dilator, COOK, Bloomington, U.S.A.) or balloon
dilator (e.g. CRETM) is the first step to treat strictures.
Cases with mild to moderate stricture usually need only
one to three repetitions of dilation [6, 9] to relieve symp-
toms. However, cases with severe stricture, especially
with long (>2-3 cm) tortuous strictures, or associated
with a diameter that precludes passage of a normal
diameter endoscope, are defined as complex strictures
and often require greater than seven to ten repetitions of
dilation procedures and/or additional treatments [6, 9].
In such cases, usually after a few sessions of simple dila-
tion [10], lesional injection of corticosteroid [7, 8, 11] is
applied, as was performed in this case. When still refrac-
tory to these treatments, incision therapy using needle
knife, scissors, and/or argon-plasma coagulation are in-
dicated for anastomotic stricture or Schatzki ring (length
<1 cm). In contrast, temporary self-expandable stent
placement is applied for strictures after caustic ingestion
or radiation injury [6, 9, 10]. In this case, incision was
not indicated because of the long stricture and there was
no need for temporary stenting as the repetitive balloon
dilations with lesional steroid injection were effective.
Regarding endoscopic dilation, caution should be paid
because adverse events, such as significant hemorrhage
(0.3–0.4% [12, 13]), perforation (0.4% [5, 12, 14]), and
rarely death (0.4%) [5], can occur. To reduce these
complications, so-called “three rules” are generally ac-
cepted. Specifically, after moderate resistance is encoun-
tered during dilation therapy with Savary-type dilators,
no greater than three consecutive dilators should be
passed in a single session. As a corollary to this ap-
proach, a conservative approach to dilation should be
undertaken. For repeat dilation sessions as needed, a lu-
minal diameter of 12 mm or larger is usually adequate
to alleviate symptoms of solid dysphagia [9]. As the
stricture of the current case was stiff and narrow, careful
and repeated dilations were performed until disappear-
ance of the symptoms in a stepwise manner.
In the recently published guideline for the manage-
ment of PNET [15], surgical exploration for PNET
≤2 cm on imaging studies is still not generally recom-
mended in MEN1/ZES. Even for PNET >2 cm in
MEN1/ZES, surgical enucleation is generally recom-
mended, while pancreatoduodenectomy is reserved for
specific selected cases. However, in cases of MEN1, mul-
tiple small nodules of NET are often recognized within
the pancreas and duodenum, as in the current case. In
such a case, the choice of surgical resection can be con-
sidered if total removal of the tumors must be pursued
or preservation of the pancreatic function should be
evaluated. Partelli [16] and Sakurai [17] et al. analyzed
the biological behavior of non-functioning pancreatic
NETs (33 cases and 14 cases, respectively) and reported
that those with size ≤20 mm are indolent and of low
oncological risk. By contrast, Gibril et al. [18] reported
up to 23% of 57 cases of MEN1 with gastrinoma that de-
veloped metastasis to the liver following the decision not
to perform resection. Gastrinomas with large size
(>20 mm) and high gastrin secretion are reported to be
aggressive [18]. Imamura et al. [19] recommended sur-
gery based on accurate localization of gastrinomas with
the SASI test in MEN1 patients. Hence, a possible surgi-
cal option is to remove only functional and aggressive
NETs, and leave others untouched. The disadvantages of
this strategy are the difficulty of accurate preoperative
diagnosis of tumor aggressiveness and of localization by
SASI in cases with vascular abnormality or with difficult,
super-selective cannulation. In the current case, even a
NET in the pancreas tail revealed faint gastrin expres-
sion, which may have responded to the SASI test. It is
also reported that pancreatic gastrinoma is rare in
MEN1, however is more aggressive than duodenal gas-
trinoma [20]. As most of MEN1 patients are still young
when they develop NETs, it is not certain that an indo-
lent NET with small size will maintain its benign nature
for its lifespan. Moreover, recent advances in the control
of glucose homeostasis after pancreatic resection is im-
proving [21]. Hence, in this case with severe symptoms
and repetitive peptic ulcer events, resection, including
total pancreatectomy, might be accepted as appropriate
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care. Future improvement is expected in the evaluation
of tumor aggressiveness, variation of the operation, and
control of the blood glucose level.
The patient in this case was first suspected of having
MEN1 based on the clinical findings of multiple peptic
lesions accompanied by high levels of serum gastrin, cal-
cium, and intact PTH, pancreatic and duodenal tumors
suspected for NETs, and a urinary tract stone. However,
it could not be confirmed until surgery and genetic test-
ing. Confirmation of a germline MEN1 mutation con-
firmed this genetic syndrome. This information was
beneficial not only for the patient but also for his family
[3], especially for the clinical follow up of an affected sis-
ter. Actually, the sister began to undergo clinical surveil-
lance of MEN1 with this opportunity, which may allow
for early detection of developing a neoplasm in her
future.
Conclusions
In conclusion, MEN1-ZES can develop severe esopha-
geal strictures, which can be treated by anti-acid therapy
and repetitive endoscopic balloon dilation. Cautious
stepwise procedures with intralesional corticosteroid in-
jection facilitated safer esophageal dilation. Additional
surgical resection of NET needs to be considered in se-
vere refractory cases. The desirable extent of surgical re-
section is arguable in cases with multiple
pancreaticoduodenal NETs, including functional ones.
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